The development of novel pharmacological therapeutics that can prevent Oria1/STIM1 puncta formation and inhibit the CaN/NFAT3 pathway may afford better protection against cardiac hypertrophy and heart failure. The gene discussed is NUP214; the disease is cardiac hypertrophy.